Physicians' Academy for Cardiovascular Education

Diabetes cardiovascular outcome trials

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof Lawrence Leiter, MD, St Michael’s Hospital, Toronto, ON, Canada - Online CME

Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.

Video navigation menu

  • CV outcomes in trials with DPP-4 inhibitors 01:13
  • More differences in results with GLP-1 receptor agonists 03:32
  • SGLT2 inhibitors and CV outcomes in trials 07:39
  • Effects pf these new drugs in the real world 12:41
  • Conclusions of diabetes drugs  13:13

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about diabetes' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand what is important when treating patients with diabetes, and what risks these patients face.

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.


Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.


Funding to produce this educational video series was provided by an unrestricted educational grant from MSD (USA) and Pfizer (USA).


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: